What is CLDWW's health score?

Calidi Biotherapeutics, Inc. (CLDWW) has a TradeApes health score of 52 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is CLDWW's estimated fair value?

Based on our 5-year discounted cash flow model, Calidi Biotherapeutics, Inc.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is CLDWW undervalued or overvalued?

Our model currently rates CLDWW as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for CLDWW... Refresh in a moment for the full analysis.

Calidi Biotherapeutics, Inc. (CLDWW)

Healthcare Inconclusive inconclusive mixed

Updated: 2026-06-05

TradeApes Score

Financial Strength

40 Weak

Operating Trend

40 Weak

Relative Value

60 Healthy

Capital Allocation

60 Healthy

Risk

80 Strong

Key Findings

+ Historically cheap — EV/EBITDA in bottom 25% of its 5-year range

Unlock Full Report →

− Weak interest coverage — earnings barely cover debt service

Unlock Full Report →

Create an account for unlimited access

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.